1. 1) Koyama, H.; Wada, T.; Nishizawa, Y.; Iwanaga, T.; Aoki, Y.; Terasawa, T.; Kosaki, G.; Yamamoto, T.; Wada, A. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39, 1403-1409 (1977).
2. 2) Warne, G.G.; Fairley, K.F.; Hobbs, J.B.; Martin, F.I.R. Cyclophosphamide-induced ovarian failure. N. Engl. J. Med. 289, 1159-1162 (1973).
3. 3) Mcguire, W.P.; Hoskins, W.J.; Brady, M.F.; Kucera, P.R.; Partridge, E.E.; Look, K.Y.; Clarke-Pearson, D.L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6 (1996).
4. 4) Kalich-Philosoph, L; Roness, H; Carmely, A; Fishel-Bartal, M; Ligumsky, H; Paglin, S; Wolf, I; Kanety, H; Sredni, B; Meirow, D. Cyclophosphamide triggers follicle activation and “burnout” ; AS101 prevents follicle loss and preserves fertility. Sci. Transl. Med. 5 (185), 185ra62 (2013).
5. 5) El-Naggar, S.A; Alm-Eldeen, A.A; Germoush, M.O; El-Boray, K.F; Elgebaly, H.A. Ameliorative effect of propolis against cyclophosphamide-induced toxicity in mice. Pharm. Biol. 53, 235-241 (2015).